MPP re­cruits three gener­ic man­u­fac­tur­ers to ex­pand use of Vi­iV's in­jectable PrEP drug

Vi­iV Health­care has teamed up with the UN-backed Med­i­cines Patent Pool and three gener­ic man­u­fac­tur­ers to ex­pand ac­cess to med­i­cine that can pre­vent HIV.

Vi­iV and the Med­i­cines Patent Pool joint­ly an­nounced Thurs­day that the MPP signed sub-li­cens­ing agree­ments with Au­robindo, Cipla and Vi­a­tris to man­u­fac­ture gener­ics of a long-act­ing form of cabote­gravir for HIV pre-ex­po­sure pro­phy­lax­is (PrEP). As a re­sult of the agree­ment, the man­u­fac­tur­ers will be able to de­vel­op, man­u­fac­ture and sup­ply gener­ic ver­sions of cabote­gravir LA in 90 coun­tries — sub­ject to reg­u­la­to­ry ap­provals.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN